Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: From the second to third generation

Expert Review of Anticancer Therapy

Volumn 8, Issue 9, 2008, Pages 1387-1398

  Tanaka, Ruriko ^a   Kimura, Shinya ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Aurora kinase; Bosutinib; Chronic myeloid leukemia; Dasatinib; Farnesyl transferase; HDAC; Heat shock protein; Imatinib; INNO 406; Nilotinib; T3151

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; ABELSON KINASE; ADAPHOSTIN; ANTILEUKEMIC AGENT; AT 9283; AURORA KINASE INHIBITOR; BOSUTINIB; CGX 653; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; DORAMAPIMOD; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HOMOHARRINGTONINE; IMATINIB; MYELOSTAT; NILOTINIB; OMACETAXINE MEPESUCCINATE; ONO 12380; PANOBINOSTAT; PHA 739358; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PROTOPORPHYRIN ZINC; SGX 393; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; CANCER INCIDENCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG STRUCTURE; ENZYME INHIBITION; GENE MUTATION; HUMAN; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PROGNOSIS; QT PROLONGATION; REVIEW; RISK FACTOR;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; POINT MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES;

EID: 55349096495     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.9.1387     Document Type: Review

References (105)

1. Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N. Engl. J. Med. 349, 1451-1464 (2003).
2. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038-1042 (2001).
3. Ottmann OG, Druker BJ, Sawyers CL et al. A Phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100, 1965-1971 (2002).
4. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880 (2001).
5. + acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor ST1571 has a unique BCR-ABL gene mutation. Blood 99, 1860-1862 (2002).
6. Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr. Opin. Hematol. 11, 35-43 (2004).
7. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105, 2640-2653 (2005).
8. Melo JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett. 249, 121-132 (2007).
9. Branford S. Chronic myeloid leukemia: molecular monitoring in clinical practice. Hematology Am. Soc. hematol. Educ. Program 376-383 (2007).
10. Shah NP, Tran C, Lee FY et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399-401 (2004).
11. Weisberg D, Manley PW, Breitenstein W et al. Characterization of AMN 107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7, 129-141 (2005).
12. Golas JM, Arndt K, Etienne D et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 3, 375-381 (2003).
13. Kimura S, Naito H, Segawa H et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106, 3948-3954 (2005).
14. Baccarani M, Saglio G, Goldman J et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108, 1809-1820 (2006).
15. + leukemias in the imatinib and post-imatinib eras. In: Bone Marrow Transplantation: New Research. Davidson DF (Ed.). Nova Publisher, NY, USA 1-38 (2006).
16. SEER Cancer Statistics Review, 1973-1991: Tables and Graphs. Ries LAG, Miller BA, Hankey BF et al. (Eds). National Cancer Institute, MD, USA 234 (1994).
17. Kantarjian HM, Deisseroth A, Kurzrock R et al. Chronic myeloid leukemia: a concise update. Blood 82, 691-703 (1993).
18. Bernstein R. Cytogenetics of chronic myelogenous leukemia. Semin. Hematol. 25, 20-34 (1988).
19. Heisterkamp N, Jenster G, ten Hoeve J et al. Acute leukaemia in bcr/abl transgenic mice. Nature 344, 251-253 (1990).
20. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824-830 (1990).
21. Elefanty AG, Hariharan IK, Cory S. Bcr-abl, The hallmark of chronic myeloid leukaemia in man, induces multiple haematopoietic neoplasms in mice. EMBO J. 9, 1069-1078 (1990).
22. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994-1004 (2003).
23. Druker BJ, Guilhot F, O'Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408-2417 (2006).
24. Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18, 132-1331 (2004).
25. + leukemic cells to the abl inhibitor STI571. J. Natl. Cancer. Inst. 92, 1641-1650 (2000).
26. Hegedus T, Orfi L, Seprodi A et al. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim. Biophys. Acta. 1587, 318-325 (2002).
27. Donato NJ, Wu JY, Stapley J et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101, 690-698 (2003).
28. White DL, Saunders VA, Dang P et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110, 4064-4072 (2007).
29. Kantarjian H, Talpaz M, O'Brien S et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103, 2873-2878 (2004).
30. + leukemia activity of imatinib mesylate. Blood 102, 2229-2235 (2003).
31. Goldman JM. Chronic myeloid leukemia - still a few questions. Exp. Hematol. 32, 2-10 (2004).
32. Talpaz M, Shah NP, Kantarjian H et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354, 2531-2541 (2006).
33. Deguchi Y, Kimura S, Ashihara E et al. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk. Res. 32, 980-983 (2008).
34. + ALL. Lancet Oncol. 8, 273-274 (2007).
35. Gambacorti-Passerini C, Gasser M, Ahmed S et al. Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies. Leukemia 19, 1267-1269 (2005).
36. Rix U, Hantschel O, Dümberger G et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110, 4055-4063 (2007).
37. Kantarjian H, Pasquini R, Hamerschlak N et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized Phase 2 trial. Blood 109, 5143-5150 (2007)
38. O'Hare T, Walters DK, Stoffregen EP et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 65, 4500-4555 (2005).
39. Kantarjian HM, Giles F, Gattermann N et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110, 3540-3546 (2007).
40. le Coutre P, Ottmann OG, Giles F et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111, 1834-1839 (2008)
41. Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood 110, 2828-2837 (2007)
42. Gambacorti-Passerini C, Kantarjian H, Bruemmendorf T et al. Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated among patients with AP and BPCML and Ph plus ALL. Blood 110, 146A-146A (2007).
43. Kimura S, Ashihara E, Maekawa T. New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Curr. Pharm. Biotechnol. 7, 371-379 (2006).
44. Horio T, Hamasaki T, Inoue T et al. Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives. Bioorg. Med. Chem. Lett. 17, 2712-2717 (2007)
45. Naito H, Kimura S, Nakaya Y et al. In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations. Leuk. Res. 30, 1443-1446 (2006).
46. + leukemia cells in the central nervous system and cyclosporine A augments its in vivo activity. Blood 109, 306-314 (2007).
47. Kantarjian HM, Cortes J, Le Coutre P et al. A Phase I study of INNO-406 in patients with advanced Philadelphia (Ph plus) chromosome-positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors. Blood 110, 144A-144A (2007).
48. Nicolini FE, Hayette S, Corm S et al. Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a 73151 BCR-ABL mutation. Haematologica 92, 1238-1241 (2007).
49. Soverini S, Colarossi S, Gnani A et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin. Cancer Res. 12, 7374-7379 (2006).
50. Jabbour E, Kantarjian H, Jones D et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20, 1767-1773 (2006).
51. Jabbour E, Kantarjian H, Jones D et al. Characteristics and outcome of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112(1), 53-55 (2008).
52. Schindler T Bornmann W, Pellicena P et al. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289, 938-942 (2000).
53. Corbin AS, Buchdunger E, Furet P, Druker BJ. Analysis of the structural basis of specificity of the Abl kinase by STI571. J. Biol. Chem. 277, 32214-32219 (2001).
54. Pricl S, Fermeglia M, Ferrone M, Tamborini E. T3151-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study. Mol. Cancer Ther. 4, 1167-1174 (2005)
55. Lee TS, Potts SJ, Kantarjian H et al. Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. Cancer 112, 1744-1753 (2008).
56. Weisberg E, Manley P, Mestan J et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Brit. J. Cancer 94, 1765-1769 (2006).
57. von Bubnoff N, Manley PW, Mestan J et al. BCR-ABL resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the ABL kinase inhibitor nilotinib (AMN107). Blood 108, 1328-1333 (2006).
58. Levinson NM, Kuchment O, Shen K et al. A Src-like inactive conformation in the ABL Tyrosine Kinase Domain. PLoS Biol. 4, e144 (2006).
59. Gumireddy K, Baker SJ, Cosenza SC et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc. Natl Acad. Sci. USA 102, 1992-1997 (2005).
60. Carter TA, Wodicka LM, Shah NP et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl Acad. Sci. USA 102, 11011-11016 (2005)
61. Kuma Y, Sabic, G, Bain J et al. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J. Biol. Chem. 280, 19472-19479 (2005)
62. O'Hare T, Druker BJ. BIRB-796 is not an effective ABL(T315I) inhibitor. Nat. Biotechnol. 23, 1209-1210 (2005).
63. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev. Mol. Cell. Biol. 4, 842-854 (2003).
64. Andrews PD, Knatko E, Moore WJ, Swedlow JR. Mitotic mechanics: the auroras come into view. Curr. Opin. Cell. Biol. 15, 672-683 (2003).
65. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev. 22, 451-464 (2003).
66. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer 4, 927-936 (2004).
67. Harrington EA, Bebbington D, Moore J. et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. 10, 262-267 (2004).
68. Young MA, Shah NP, Chao LH et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res. 66, 1007-1014 (2006).
69. Cheetham GM, Chariton PA, Golec JM, Pollard JR. Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett., 251, 323-329 (2007)
70. Shah NP, Skaggs BJ, Branford S et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Invest. 117, 2562-2569 (2007).
71. Giles FJ, Cortes J, Jones D et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109, 500-502 (2007).
72. Fancelli D, Moll J, Varasi M et al. 1,4,5,6-tetrahydropyrrolo [3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J. Med. Chem. 49, 7247-7251 (2006).
73. Modugno M, Casale E, Soncini C et al. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res. 67, 7987-7990 (2007).
74. Gontarewicz A, Balabanov S, Keller G et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 111, 4355-4364 (2008).
75. Squires MS, Reule M, Curry J et al. AT9283, a potent inhibitor of bcr-abl T315I, is active in CML models. Presented at: 2008 Annual Meeting of American Association of Cancer Research. CA, USA, 12-16 April 2008 (Abstract 2820).
76. O'Brien S, Kantarjian H, Koller C et al. Sequential homoharringtonine and interferon-α in the treatment of early chronic phase chronic myelogenous leukemia. Blood 93, 4149-4153 (1999)
77. Legros L, Hayette S, Nicolini FE et al. BCR-ABL (T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge? Leukemia 21, 2204-2206 (2007).
78. de Lavallade H, Khorashad JS, Davis HP et al. Interferon-α or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood 110, 2779-2780 (2007).
79. Quintás-Cardama A, Cortes J. Homoharringtonine for the treatment of chronic myelogenous leukemia. Expert. Opin. Pharmacother. 9, 1029-1037 (2008).
80. O'Hare T, Eide CA, Tyner JW et al. SGX393 inhibits the CML mutant Bcr-Abl T315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc. Natl Acad. Sci. USA 105, 5507-5512 (2008).
81. Gorre ME, Enwood-Yen K, Chiosis G, Rosen N, Sawyers CL. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 100, 3041-3044 (2002)
82. Peng C, Brain J, Hu Y et al. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 110, 678-685 (2007).
83. Mayerhofer M, Florian S, Krauth MT et al. Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. Cancer Res. 64, 3148-3154 (2004).
84. Mayerhofer M, Gleixner KV, Mayerhofer J et al. Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood 111, 2200-2210 (2008).
85. Nimmanapalli R, Fuino L, Bali P et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 63, 5126-5135 (2003).
86. George P, Bali P, Annavarapu S et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105, 1768-1776 (2005).
87. Fiskus W, Pranpat M, Bali P et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl- expressing human leukemia cells. Blood 108, 645-652 (2006).
88. Fiskus W, Pranpat M, Balasis M et al. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin. Cancer Res. 12, 5869-5878 (2006).
89. Carew JS, Nawrocki ST, Kahue CN et al. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 110, 313-322 (2007)
90. Copland M, Pellicano F, Richmond L et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 111, 2843-2853 (2008).
91. Dasmahapatra G, Nguyen TK, Dent P, Grant S. Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl. Leuk. Res. 30, 1263-1272 (2006).
92. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 66, 6468-6472 (2006).
93. Carter BZ, Mak DH, Shi Y et al. Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Cell Cycle 5, 2223-2229 (2006).
94. Bartholomeusz GA, Talpaz M, Kapuria V et al. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood 109, 3470-3478 (2007).
95. Zhang H, Trachootham D, Lu W et al. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia 22, 1191-1199 (2008).
96. Tseng PH, Lin HP, Zhu J et al. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. Blood 105, 4021-4027 (2005).
97. Dong S, Kang S, Lonial S et al. Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070. Leukemia 22, 572-577 (2008).
98. Zhou T, Parillon L, Li F et al. Crystal structure of the T315I mutant of AbI kinase. Chem. Biol. Drug Des. 70, 171-181 (2007)
99. + human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Mol. Pharmacol. 72, 788-795 (2007).
100. Neviani P, Santhanam R, Oaks JJ et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J. Clin. Invest. 117, 2408-2421 (2007)
101. Puissant A, Grosso S, Jacquel A et al. Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol. FASEB J. 22(6), 1894-1904 (2008).
102. Sillaber C, Mayerhofer M, Böhm A et al. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur. J. Clin. Invest. 38, 43-52 (2008)
103. Van Etten RA, Chan WW, Zaleskas VM et al. DCC-2036: a novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy against BCR-ABL T3151 in vivo and in a CML mouse model. Blood 110, 142A-143A (2007)
104. Komarova NL, Wodarz D. Drug resistance in cancer: principles of emergence and prevention. Proc. Natl Acad. Sci. USA 102, 9714-9719 (2005).
105. Valent P. Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. Br. J. Haematol. (2008) (Epub ahead of print).